UPCC 36424 Phase 2, Open-Label, Multicenter, Dose-Optimization Study of the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Volasertib in Combination With Decitabine in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
The purpose of this study is to test the safety and tolerability of volasertib combined with decitabine in participants with relapsed/refractory acute myeloid leukemia.
We would like to rely on Advarra IRB as the IRB of record for this study.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
11 Sep 2024.
Study ID: 856373
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
